3061-88-9

Basic information

• Product Name: L-ALANYL-L-TYROSINE
• Synonyms: alanyltyrosine;ALA-TYR;H-ALA-TYR-OH;L-ALA-TYR;L-ALANYL-L-TYRISINE;L-ALANYL-L-TYROSINE;L-ALANINE-L-TYROSINE;N-L-alanyl-L-tyrosine
• CAS NO: 3061-88-9
• Molecular Formula: C₁₂H₁₆N₂O₄
• Molecular Weight: 252.27
• EINECS: 221-305-7
• Product Categories: Biochemistry;Oligopeptides;Peptide Synthesis;Dipeptides;Dipeptides and Tripeptides;Peptides
• Mol File: 3061-88-9.mol

Chemical Properties

• Melting Point: 238-240℃ (decomposition)
• Boiling Point: 558 °C at 760 mmHg
• Flash Point: 291.2 °C
• Appearance: /
• Density: 1.315 g/cm³
• Vapor Pressure: 2.76E-13mmHg at 25°C
• Refractive Index: 22 ° (C=2, 5mol/L HCl)
• Storage Temp.: −20°C
• Solubility: almost transparency in 5mol/L HCl
• PKA: 3.03±0.10(Predicted)
• Water Solubility: 17.99g/L at 20℃
• CAS DataBase Reference: L-ALANYL-L-TYROSINE(CAS DataBase Reference)
• NIST Chemistry Reference: L-ALANYL-L-TYROSINE(3061-88-9)
• EPA Substance Registry System: L-ALANYL-L-TYROSINE(3061-88-9)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 3061-88-9(Hazardous Substances Data)

Usage

Uses

Used in Intravenous Nutrition:
L-ALANYL-L-TYROSINE is used as a tyrosin source in the intravenous nutrition of the rate. It serves as an essential component in providing the necessary nutrients for the proper functioning and maintenance of the body's systems.
Used in Pharmaceutical Industry:
L-ALANYL-L-TYROSINE is used as an active pharmaceutical ingredient for the development of various drugs. Its unique properties make it a valuable compound in the creation of medications targeting specific health conditions.
Used in Cosmetics Industry:
L-ALANYL-L-TYROSINE is also utilized in the cosmetics industry for its skin-friendly properties. It is often incorporated into skincare products to provide nourishment and support the skin's natural functions.

Flammability and Explosibility

Notclassified

InChI:InChI=1/C12H16N2O4/c1-7(13)11(16)14-10(12(17)18)6-8-2-4-9(15)5-3-8/h2-5,7,10,15H,6,13H2,1H3,(H,14,16)(H,17,18)/t7-,10-/m0/s1

Upstream product

• 949-67-7 L-tyrosine ethyl ester 
• 563-76-8 α-bromopropionyl bromide 
• 91307-60-7 N-(N-benzyloxycarbonyl-L-alanyl)-L-tyrosine benzyl ester 
• 13122-97-9 N-benzyloxycarbonyl-L-alanyl-L-tyrosine 

Downstream Products

• 135924-15-1 N-(dibutyloxyphosphoryl)-L-alanyl-L-tyrosine 
• 92455-61-3 Boc-Cys(MBzl)-Ala-Gly-Ala-Tyr-OH 
• 144006-24-6 Ala-Tyr-OMe 
• 92455-68-0 Cys-Ala-Gly-Ala-Tyr-TFA 
• 70529-66-7 N-acetyl-L-alanyl-L-tyrosine 
• 952312-48-0 C₁₆H₂₀N₂O₅ 

Relevant articles and documents

The Use of Crown Ethers in Peptide Chemistry IV. Solid Phase Synthesis of Peptides Using Peptide Fragments Nα Protected With 18-Crown-6

The conditions under which peptide synthesis by the fragment condensation approach in the solid phase can be carried out using crown ethers as non-covalent protecting groups for the Nα amino group of peptides were determined.The dipeptide Gly-Gly was complexed with 18-crown-6 to establish the feasibility of this new protection scheme and to optimise the reaction conditions.Nearly quantitative incorporation of the complex onto resin-bound amino acids possessing either proline or an Nα-alkylated amino acids was achieved using DCM as the activation and coupling reactions solvent.The use of DMF as the solvent and resin-bound primary amino acids were found detrimental to the reaction yields due to the removal of the crown ether protection.Extending the length of the peptide fragment to model pentapeptide complexes bearing no reactive functionalities on the side-chain gave essentially quantitative incorporation yields in the coupling reactions to both resin-bound amino acids and short peptides.The non-covalent nature of the protection afforded by the crown molecule allowed its mild removal from resin-bound complexes by rapid treatments with 1percent DIEA solutions.Thus the continuation of chain assembly was possible.The results obtained served as the basis for extending the concept of non-covalent protection to the side chains of Lys and Arg containing peptides.

Amino Acids and Peptides. III. Synthesis of Model Peptides Related to Cytochrome P-450

Various tetra- and pentapeptides with Cys and Ser (Thr, Tyr, His) at the N- and C-terminals, respectively, were synthetized as model peptides of the apoprotein of cytochrome P-450.The optical spectra of synthetic peptide-hemin complexes were measured and the results are discussed.Keywords - cytochrome P-450; synthetic Cys-containing peptide; peptide-hemin complex; optical spectrum of peptide-hemin complex

Medicament which antagonizes the action of gastrin and related polypeptides

The present invention relates to a method of treating diseases and particularly gastroduodenal ulcers linked to an hypersecretion of gastrin, and to polypeptide amide derivatives which can be used in this method as therapeutic agents and more specifically as antagonists of the action of gastrin and related polypeptides relative to their specific biological receptors. This method comprises administering a therapeutically effective amount of a polypeptide amide derivative of general formula: STR1 in which R1 represents a hydrogen atom or an acyl radical and R2 represents a substituted or unsubstituted aryl radical e.g. nitrophenyl group or dinitrophenyl group such as 2-nitrophenyl or 2-4-dinitrophenyl.